Description

National

Description on indicator: Prevalence of hepatitis B surface antigen (HBsAg+) among the general population.

Children under-5

This indicator is a performance measure for the SDG targets and WHO HBV/HCV elimination targets. For the WHO targets, it The 2020 target is 1<% prevalence and the 2030 target is <0.1%.

Description of indicator: Prevalence of hepatitis B surface antigen (HBsAg+) among children under-5 years old.

Other sub-populations

Prevalence of hepatitis B surface antigen (HBsAg+) is also reported for other sub-populations based on available data, including:

• People who inject drugs
• People living with HIV
• Men who have sex with men
• Prisoners
• Pregnant women

Additional sub-populations can be added as more data becomes available. 

Sources

National

Modelled

All country dashboards show show Institute of Health Metrics and Evaluation (IHME) modelled estimates for chronic HBsAg prevalence among children under-5 yrs for 1990-2019.

Institute for Health Metrics and Evaluation. Global Burden of Disease Project, 2019. Available at: http://ghdx.healthdata.org/gbd-results-tool. 

Survey/reported

• European Centre for Disease Prevention and Control. Systematic review on hepatitis B and C prevalence in the EU/EEA.  Stockholm: ECDC; 2016.

Only estimates with a risk of bias risk of bias score ≥4 or pooled estimates were included. Pooled estimates were considered "Modelled" estimates.

• European Centre for Disease Prevention and Control. Monitoring the responses to hepatitis B and C epidemics in EU/EEA member states, 2019. Stockholm: ECDC; 2020. Studies from 2016-2017 (the most recent ones included) were used from this report as earlier studies were included in the 2016 systematic review. Reference links were not included in this report, so all reported estimates are linked back to the main report.
• Population-based HIV impact studies were reviewed as some studies included HBsAg and anti-HCV screening. More on the population-based impact studies can be found at: https://phia.icap.columbia.edu/. When estimates for multiple age ranges were reported, all ages was selected when available, and if not available, then ages 15+ was used. In most cases, confidence intervals for anti-HCV prevalence were not reported. 

Children under-5 years old

Modelled

All country data dashboards show Institute of Health Metrics and Evaluation (IHME) modelled estimates for chronic HBsAg prevalence among children under-5 yrs for 1990-2019. 

Institute for Health Metrics and Evaluation. Global Burden of Disease Project, 2019. Available at: http://ghdx.healthdata.org/gbd-results-tool. 

WHO has also published modelled estimates for all countries in 2015:

WHO (2015). Global Health Observatory. https://www.who.int/data/gho/data/indicators/indicator-details/GHO/hepatitis-b-surface-antigen-(hbsag)-prevalence-among-children-under-5-years

Survey/reported

Source: WHO WPRO. Personal communication with Po-lin Chan, Medical Officer for Viral Hepatitis, World Health Organization Western Pacific Regional Office.

National data may come from surveys that span several years, we used the most recent year when available.

National data from WHO WPRO may include children from older ages but we assumed this data was representative of children under-5.

Pregnant women

• European Centre for Disease Prevention and Control. Systematic review on hepatitis B and C prevalence in the EU/EEA. Stockholm: ECDC; 2016.

Only estimates with a risk of bias risk of bias score ≥2 or pooled estimates were included. Pooled estimates were considered "Modelled" estimates.

• European Centre for Disease Prevention and Control. Monitoring the responses to hepatitis B and C epidemics in EU/EEA member states, 2019. Stockholm: ECDC; 2020. Studies from 2016-2017 (the most recent ones included) were used from this report as earlier studies were included in the 2016 systematic review. Reference links were not included in this report, so all reported estimates are linked back to the main report.

MSM

• European Centre for Disease Prevention and Control. Systematic review on hepatitis B and C prevalence in the EU/EEA. Stockholm: ECDC; 2016.

Only estimates with a risk of bias risk of bias score ≥2 or pooled estimates were included. Pooled estimates were considered "Modelled" estimates.

• European Centre for Disease Prevention and Control. Monitoring the responses to hepatitis B and C epidemics in EU/EEA member states, 2019. Stockholm: ECDC; 2020. Studies from 2016-2017 (the most recent ones included) were used from this report as earlier studies were included in the 2016 systematic review. Reference links were not included in this report, so all reported estimates are linked back to the main report.

Prisoners

• European Centre for Disease Prevention and Control. Systematic review on hepatitis B and C prevalence in the EU/EEA. Stockholm: ECDC; 2016.

Only estimates with a risk of bias risk of bias score ≥2 or pooled estimates were included. Pooled estimates were considered "Modelled" estimates.

• European Centre for Disease Prevention and Control. Monitoring the responses to hepatitis B and C epidemics in EU/EEA member states, 2019. Stockholm: ECDC; 2020. Studies from 2016-2017 (the most recent ones included) were used from this report as earlier studies were included in the 2016 systematic review. Reference links were not included in this report, so all reported estimates are linked back to the main report.